December 1988

Measles in Hospitalized African Children With Human Immunodeficiency Virus

Author Affiliations

Division of Infectious Diseases Blalock 1111 The Johns Hopkins Hospital 600 N Wolfe St Baltimore, MD 21205
Division of Immunization Freeway Park, Room 346 Centers for Disease Control Atlanta, GA 30333
International Health Program Office Centers for Disease Control Atlanta, GA 30333
The Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases Bethesda, MD 20892
Projet SIDA Kinshasa, Zaire

Am J Dis Child. 1988;142(12):1271-1272. doi:10.1001/archpedi.1988.02150120025021

Sir.—Due to the increasing number of children infected with the human immunodeficiency virus (HIV), there has been concern regarding the interaction of HIV and endemic childhood diseases.1,2 Measles is a major cause of childhood morbidity and mortality in Africa. Attack rates reach 100% in unvaccinated children, and estimates of fatality rates range from 2% to 34%. Although measles vaccine is recommended by the World Health Organization for all children at 9 months of age in developing countries, questions have been raised about the use of this live viral vaccine in HIV-infected children. The decision to use the vaccine depends on its safety and efficacy as well as on the risk and severity of measles disease in these children. Since measles can be severe in immunocompromised children, concomitant HIV and measles infection may be associated with increased morbidity and mortality. To investigate the severity of measles in HIV-infected children, we studied

First Page Preview View Large
First page PDF preview
First page PDF preview